354 related articles for article (PubMed ID: 24788576)
21. Histological and immunohistochemical analyses of osteoclast maturation in giant cell tumor of bone.
Agawa R; Kato I; Kawabata Y; Takeyama M; Fujii S
Pathol Res Pract; 2024 Feb; 254():155128. PubMed ID: 38244437
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
[TBL] [Abstract][Full Text] [Related]
24. Updated concepts in treatment of giant cell tumor of bone.
van der Heijden L; Lipplaa A; van Langevelde K; Bovée JVMG; van de Sande MAJ; Gelderblom H
Curr Opin Oncol; 2022 Jul; 34(4):371-378. PubMed ID: 35837707
[TBL] [Abstract][Full Text] [Related]
25. Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone.
Palmerini E; Staals EL; Jones LB; Donati DM; Longhi A; Randall RL
Curr Treat Options Oncol; 2020 Jul; 21(8):68. PubMed ID: 32623530
[TBL] [Abstract][Full Text] [Related]
26. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
27. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
[TBL] [Abstract][Full Text] [Related]
28. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
29. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
[TBL] [Abstract][Full Text] [Related]
30. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
[TBL] [Abstract][Full Text] [Related]
31. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
32. Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.
Borkowska AM; Szumera-Ciećkiewicz A; Szostakowski B; Pieńkowski A; Rutkowski PL
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565419
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Utility of Genetic and Immunohistochemical
Wągrodzki M; Tysarowski A; Seliga K; Wojnowska A; Stepaniuk M; Castañeda Wysocka P; Makuła D; Pieńkowski A; Szostakowski B; Zub R; Rutkowski P
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055156
[TBL] [Abstract][Full Text] [Related]
34. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
[TBL] [Abstract][Full Text] [Related]
35. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
36. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
37. Giant cell tumour of bone: new treatments in development.
López-Pousa A; Martín Broto J; Garrido T; Vázquez J
Clin Transl Oncol; 2015 Jun; 17(6):419-30. PubMed ID: 25617146
[TBL] [Abstract][Full Text] [Related]
38. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
39. Giant cell tumor of bone.
Raskin KA; Schwab JH; Mankin HJ; Springfield DS; Hornicek FJ
J Am Acad Orthop Surg; 2013 Feb; 21(2):118-26. PubMed ID: 23378375
[TBL] [Abstract][Full Text] [Related]
40. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
